Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ONC
BUYBeOne Medicines AG · Healthcare · Switzerland · $33.8B · Avg Vol: $110M/d
COMPANY DESCRIPTION
BeOne Medicines AG, while not publicly traded under the provided ticker and country combination, is likely a pharmaceutical or biotechnology company focused on developing novel medical treatments. Its competitive edge would stem from proprietary research, specialized drug pipelines, and a focus on addressing unmet medical needs. This positions it as an innovative player aiming to bring new therapies to market within the healthcare sector.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.4B | 2.5B | 3.8B | 5.3B | 55.7% | 5.7B | 6.5B | 7.5B | 18.1% |
| EPS | -15.73 | -276.80 | -120.62 | -89.16 | 39.48 | — | 4.42 | 6.54 | 9.69 | -50.5% |
| Shares | — | 94.9M | 94.9M | 94.9M | 94.9M | 0.0% | 94.9M | — | — | — |
| Debt | — | 596.7M | 930.2M | 1.1B | 1.1B | 22.4% | 2.1B | — | — | — |
| Equity | — | 4.4B | 3.5B | 3.3B | 4.4B | -0.2% | — | — | — | — |
| Op CF | — | -1.5B | -1.2B | -140.6M | 1.1B | — | 1.3B | — | — | — |
| Inv CF | — | 1.1B | 60.0M | -548.4M | -276.2M | — | — | — | — | — |
| Fin CF | — | -19.0M | 416.5M | 193.4M | 1.1B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ONC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ONC | BeOne Medicines AG(you) | $33.8B | 70 | BUY |
| 0K10.L | Mettler-Toledo International Inc. | $33.1B | 57 | HOLD |
| 0QNO.L | Lonza Group AG | $47.0B | 61 | HOLD |
| BANB.SW | Bachem Holding AG | $6.7B | 52 | HOLD |
| BBZA.DE | BB Biotech AG | $3.1B | 99 | STRONG BUY |
| BSLN.SW | Basilea Pharmaceutica AG | $794M | 84 | STRONG BUY |
| IDIA.SW | Idorsia Ltd | $2.2B | 33 | SELL |
| CRSP | CRISPR Therapeutics AG | $4.6B | 14 | STRONG SELL |
| PHVS | Pharvaris N.V. | $2.4B | 26 | SELL |
| GALD.SW | GALDERMA GROUP N | $49.5B | 70 | BUY |
Peer medians: ROE 10.5% · P/E 23.9x · Gross margin 47.9%